<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00041093</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0127S</org_study_id>
    <secondary_id>NCI-2012-02476</secondary_id>
    <secondary_id>CDR0000069442</secondary_id>
    <secondary_id>GOG-0127S</secondary_id>
    <secondary_id>GOG-0127S</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00041093</nct_id>
  </id_info>
  <brief_title>Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer</brief_title>
  <official_title>A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>GOG Foundation</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of docetaxel in treating patients who have&#xD;
      persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the antitumor activity of docetaxel in patients with persistent or recurrent&#xD;
      squamous cell carcinoma of the cervix.&#xD;
&#xD;
      II. Determine the toxicity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then&#xD;
      annually thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <primary_completion_date type="Actual">October 23, 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of progression-free interval</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and duration of objective response as assessed on radiologic scan</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of observed adverse effects</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival time</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Cervical Squamous Cell Carcinoma, Not Otherwise Specified</condition>
  <condition>Recurrent Cervical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment (docetaxel)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (docetaxel)</arm_group_label>
    <other_name>Docecad</other_name>
    <other_name>RP56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Taxotere Injection Concentrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed persistent or recurrent squamous cell carcinoma of the cervix&#xD;
&#xD;
          -  Progressive disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable target lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Tumors within a previously irradiated field are not considered target lesions&#xD;
&#xD;
          -  One prior systemic chemotherapeutic regimen for advanced, metastatic, or recurrent&#xD;
             squamous cell carcinoma of the cervix required&#xD;
&#xD;
               -  Chemotherapy administered as a radiosensitizer in conjunction with primary&#xD;
                  radiotherapy is not considered a systemic chemotherapy regimen&#xD;
&#xD;
          -  Ineligible for a higher priority GOG protocol (e.g., any active Phase III GOG protocol&#xD;
             or GOG-0076)&#xD;
&#xD;
          -  Performance status - GOG 0-2&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2.5 times ULN&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No unstable angina, myocardial infarction, or new cardiac arrhythmia within the past 6&#xD;
             months&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No greater than grade 1 sensory and motor neuropathy&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  At least 3 weeks since prior biologic or immunologic therapy directed at malignant&#xD;
             tumor&#xD;
&#xD;
          -  One prior noncytotoxic regimen (e.g., monoclonal antibodies, cytokines, or&#xD;
             small-molecule signal transduction inhibitors) for recurrent or persistent disease&#xD;
             allowed&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No prior docetaxel&#xD;
&#xD;
          -  No more than 1 prior cytotoxic chemotherapy regimen&#xD;
&#xD;
          -  At least one week since prior hormonal therapy directed at malignant tumor&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  Recovered from recent prior surgery&#xD;
&#xD;
          -  At least 3 weeks since any prior therapy directed at malignant tumor&#xD;
&#xD;
          -  No prior anticancer therapy that would preclude study&#xD;
&#xD;
          -  No concurrent amifostine or other protective agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Garcia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 8, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

